Dr. Kayane Mheidly

Qualification and Experience

Dr. Kayane Mheidly began her medical studies in 2004 at the Lille 2 Faculty of Medicine in France. She received her medical degree and postgraduate competence in haematology (malignant haematology and blood disorders) with honours from the Rennes 1-France Faculty of Medicine. She is a fellowship-PhD candidate at the Rennes 1 University Hospital's Institution of Haematology, a well-known department in France for the treatment of Lymphoma, LGL Leukemia, multiple myeloma, acute Leukemia, and bone marrow transplantation (114 autologous stem cells transplantations and 58 allogenic stem cells transplantations per year). Therefore, her professional qualifications are Specialized Diploma in Haematology-French Board, University Diploma of Thrombosis/Clinical Haemostasis, University Diploma of Supportive/Palliative Care, European Haematology Association (EHA) master class, Master 1 in fundamental research, Fellowship-PhD: University hospital of Rennes, and Faculty of medicine of Lille 2-Henri Warembourg -France.

Dr. Kayane has more than ten years of experience in the diagnosis and treatment of haematological illnesses, including stem cell transplantation, immunotherapy, targeted therapy, inpatient and outpatient care, chronic and acute haematological malignancies, and benign haematology. She makes every effort to tailor the treatment to the disease's molecular and cytogenetic profile, as well as the patient's tolerance and history. Dr. Kayane Mheidly has worked as Consultant Hematology, Clemenceau Medical Center Dubai. Her present assignment is Consultant - Clinical Haematology with Burjeel Medical city, Abu Dhabi, United Arab Emirates.

Reasons to Avail Online Consultation with Kayane Mheidly

It is extremely important and beneficial to have an online consultation with your treating doctor before beginning any Hematology treatment. We've compiled a list of the top reasons to schedule an online consultation with Dr. Kayane Mheidly-

• She is gifted and dedicated to providing the best possible care and service to all of her patients.
• She aims to achieve the right balance between therapeutic efficacy, safety, and cost when treating all of her patients.
• Families are given a lot of attention when it comes to holistic patient care and getting better treatment results.
• On a first-come, first-served basis, teleconsultations with Dr. Kayane Mheidly are available.
• Dr. Kayane Mheidly is highly recommended by international patients who frequently consult her for hematological issues.
• When it is about finding a specialist for a consultation, Dr. Kayane's significant experience in the field of Hematology, having personally managed numerous Hematological treatments, is a major bonus.
• The specialist makes sure that the patients' anxiety and treatment phobia are adequately controlled, and encourages them to openly share their problems with a caregiver.
• As the consultations are to be scheduled with Dr. Kayane Mheidly, it is pertinent to note that she is multilingual, which is a huge plus. She has full professional proficiency in French, English, and Arabic.

Contribution to Medical Science

Her professional memberships are LYSA (Lymphoma Study Association), SFH (French Society of Haematology), IFM (French Intergroup of Multiple Myeloma), and EMA/ESH (Emirates Medical Association / Emirates Society of Haematology). Poster presentations and Research and Publications by Dr. Kayane Mheidly are 

• Poster at the COMETH-GEHT Hemostasis Congress: Atypical thrombosis and mutations of the CALR September 2014.
• Poster at the congress of the SFH (French Society of Hematology): Incidence of CALR mutations in intra-abdominal thrombosis and cerebral thrombophlebitis May 2015.
• Poster at the American Society of Hematology (ASH) Conference: The Place of Adjuvant Chemotherapy in the Treatment of Solitary Bone Plasmacytoma December 2016.
• Poster at the SFH Congress: La place de la chimiothérapie adjuvante dans le traitement du plasmocytome solitaire osseux March 2017.
• Publication of the Article: Traitement de première ligne du lymphome folliculaire in the review Horizons Hémato March 2017.